ABSTRACT Introduction. We sought to determine if adoption of the Z0011 criteria was associated with removal of more sentinel lymph nodes (SLNs). Methods. In a retrospective review of a prospective database of breast cancer patients treated at our institution from 2006 to 2013, we identified 5213 eligible patients who elected to undergo breast-conserving surgery; 2372 were treated pre-Z0011 and 2841 post-Z0011. Clinicopathologic factors were collected, and univariate and multivariate models were fit to identify variables associated with number of SLNs removed. Results. Median patient age, 60 years, did not differ between groups. Median tumor size was similar in both groups: 1.1 (0.05-5.0) cm in the pre-Z0011 group and 1.2 (0.1-5.2) cm in the post-Z0011 group. The mean number of SLNs excised in the pre-Z0011 patients was 2.8 compared with 2.9 in post-Z0011 patients (p = 0.01). Three or fewer lymph nodes were removed in 1771 (75 %) pre-Z0011 patients compared with 2006 (71 %) post-Z0011 patients (p = 0.01). Factors associated with the removal of more SLNs on multivariate analysis included adoption of ACOSOG Z0011 criteria (p = 0.03), young age (p B 0.0001), and large tumor size (p = 0.0005). Axillary lymph node dissection (ALND) was performed in 379 (16 %) patients pre-Z0011 compared with 68 (2 %) nodepositive post-Z0011 patients (p \ 0.0001). Conclusions. Since the adoption of Z0011 criteria, we found significantly fewer patients undergoing ALND for positive SLNs. We noted a significant, slight shift in the removal of C4 SLNs. The Z0011 criteria were not associated with a clinically significant increase in the number of SLNs removed.
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in clinically node-negative breast cancer patients. The ability of SLNB to accurately predict the status of other axillary nodes has been validated in several studies. 1 The NSABP B32 trial showed that SLNB was equal to axillary lymph node dissection (ALND) in the ability to accurately stage the axilla in clinically nodenegative patients. Veronesi et al. showed that the overall survival (OS) was similar between node-negative patients who had a SLNB alone compared with those who had an ALND. 2 The 10-year follow-up results of this randomized, control study confirmed no difference in survival between the group that had SLNB alone and the group that had ALND, thus confirming that ALND could be avoided in patients with a negative SLNB. 3 Since the incorporation of SLNB into axillary staging, ALND is reserved for those patients with clinically palpable nodes or in whom SLNB is positive.
Management of a positive sentinel lymph node (SLN) changed with the ACOSOG Z0011 trial. 4 This prospective, phase III, noninferiority trial was first presented at the American Society of Clinical Oncology meeting in June 2010 and subsequently published in February 2011. It randomized patients with T1-2, clinically node-negative cancers who had a positive SLNB to completion ALND versus no ALND. Eligible patients had to undergo breastconservation therapy (BCT), whole-breast irradiation, and systemic therapy. During a 5-year period, 445 patients were randomized to ALND and 446 to no ALND. At a median follow-up of 6.3 years, there was no difference between groups with respect to nodal or in-breast recurrence and disease-free survival (DFS) or OS. In early-stage, clinically node-negative patients undergoing BCT, the need for ALND is now determined by the number of positive SLNs in patients who meet the ACOSOG Z0011 criteria. 4 SLNB removes an average of two lymph nodes in most studies. 5 However, several recent studies have identified factors associated with the removal of additional nodes at the time of SLNB. [6] [7] [8] Chagpar et al. found that large tumor size and surgeon inexperience with SLNB were associated with the removal of more sentinel nodes. 6 Young patient age and large tumor size were cited by Port et al. as factors that biased surgeons to remove extra lymph nodes. 7 Recently, the ACOSOG Z0011 trial has been examined as a potential bias for removing additional sentinel nodes. Robinson et al. found no statistical difference in the median number of SLNs removed before or after publication and presentation of the ACOSOG Z0011 trial, and a significant decrease in completion axillary node dissection. 9 One of the benefits of SLNB is the reduction of lymphedema often associated with an ALND, but if a greater number of sentinel nodes are being removed, then this may ultimately contribute to a reduction in this benefit. We examined whether the adoption of the ACOSOG Z011 criteria at our institution has affected the number of sentinel nodes removed and its effect on the rate of ALNDs performed.
METHODS
A retrospective review of a prospectively maintained database was performed in 5213 patients who were eligible for and elected to undergo BCT at a single institution between January 2006 and December 2013. The ACOSOG Z0011 criteria were institutionally adopted in August 2010. Our study group consisted of 2372 patients in the pre-Z0011 cohort (January 2006-December 2009) and 2841 patients in the post-Z0011 cohort (August 2010-December 2013). Fifteen surgeons performed SLNB using dual tracer mapping with Tc-99 labeled sulfur colloid and/or isosulfan blue dye. The Memorial Sloan Kettering Cancer Center technique for SLNB has been previously described. 10 All nodes that were blue, ''hot,'' or palpable were considered SLNs and removed.
Patient, tumor, and treatment variables were collected for both cohorts to determine factors associated with the number of SLNs removed. Pre-Z0011 and post-Z0011 cohorts were compared using Chi square and Wilcoxon rank-sum tests. Univariate linear regression, controlling for surgeon using a random effect, was performed to identify variables associated with number of SLNs removed. Multivariate linear regression was used to assess the association between the adoption of ACOSOG Z0011 and the number of SLNs removed after adjusting for known confounders. All analysis was performed in SAS 9.4 (SAS Institute, Cary, NC), and p values \0.05 were considered significant.
RESULTS
A total of 5213 patients were included for analysis. Patients who had a sentinel node procedure, but no nodes identified on pathologic examination, were excluded (n = 14). The clinical pathologic features for the pre-and post-Z0011 cohorts are summarized in Table 1 The mean number of SLNs excised in the pre-Z0011 patients was 2.8 compared with 2.9 in the post-Z0011 patients (p = 0.01). Figure 1a shows the distribution of SLNs excised as a categorical variable of 1-3 SLNs versus C4 SLNs excised. Four or more SLNs were removed in 601 (25.3 %) pre-Z0011 patients compared with 835 (29.4 %) post-Z0011 patients (p = 0.01). Figure 1b shows the distribution of the axillary procedure performed. In the pre-Z0011 cohort, 379 (16.0 %) had a completion axillary lymph node dissection (cALND) compared with 68 (2.4 %) patients in the post-Z0011 group (p \ 0.0001).
The univariate analysis is shown in Table 2 . We found younger age (p \ 0.0001), larger tumor size (p \ 0.0001), the adoption of ACOSOG Z0011 criteria (p = 0.03), and ECE C 2 (p \ 0.0001) to be significantly associated with removal of additional sentinel nodes.
The multivariate analysis is shown in Table 3 . Factors associated with the removal of additional SLNs on multivariate analysis remained young age (p \ 0.0001), large tumor size (p \ 0.0001), and ECE C 2 (p = 0.001). Adoption of the Z0011 criteria also was significantly associated with the removal of more SLNs (p = 0.03), but the effect was not clinically significant (0.12 additional SLNs). Figure 2a shows the mean number of SLNs removed stratified by age. An increasing number of SLNs was removed with decreasing age. In addition, in each age category, more SLNs were removed in the post-Z0011 cohort versus the pre-Z0011 cohort. Figure 2b shows the mean number of SLNs removed stratified by tumor size. An increasing number of SLNs was removed with increasing tumor size. In addition, for each tumor size, additional SLNs were removed in the post-Z0011 cohort versus the pre-Z0011 cohort. 
DISCUSSION
The NSABP B32 trial showed that SLNB was equivalent in OS and DFS compared with ALND. 11 Although the median number of SLNs described in the literature is between 2 and 3, the number of actual SLNs removed is affected by several factors, including technique, experience, clinical factors, and the surgeon's perceived risk of axillary metastasis.
2,11 Schrenk et al. noted that the pathologic status of the axilla was accurately determined by the first and second SLNs in 99 % of patients. 8 In addition, the authors noted that removing more than three lymph nodes did not increase the chance of finding a positive node. Additionally, Yi et al. reported that [99 % of positive SLNs were found in the first 5 SLNs removed. 12 Several studies have reported factors associated with the number of nodes removed during SLNB. Chagpar et al. found in a study of 4131 patients that palpable tumors (p \ 0.001), dermal injection of radiocolloid tracer (p = 0.001), and surgeon inexperience (p \ 0.007) were independently associated with the removal of C4 SLNs on multivariate analysis. 6 Schrenk et al. evaluated whether variables, including tumor size, histologic characteristics, receptor status, age, and type of lymphatic mapping influenced the number of SLNs removed. 8 This study found no association between the variables studied and the number of SLNs removed. Port et al. identified age and large tumor size as significantly associated with removal of more sentinel nodes at our institution. 7 In the 4103 patients undergoing SLNB, more lymph nodes were removed for patients B50 years of age versus [50 years (4.6 nodes vs. 4.2 nodes; p = 0.006) and in those with larger tumors (6.3 nodes for T2 tumors vs. 4.3 nodes for T1 tumors; p \ 0.006). Our study findings are consistent with this earlier report. Yi et al. found that certain factors required increased SLN sampling to achieve 99 % recovery of all positive SLNs. Patients with mixed ductal and lobular histology required two additional SLNs versus patients with pure ductal or lobular histology (7 vs. 5 SLNs, p \ 0.001), Caucasian ethnicity required two additional SLNs versus non-Caucasian ethnicity (6 vs. 4 SLNs, p \ 0.001), and inner quadrant tumors required three additional SLNs versus outer quadrant tumors (8 vs. 5 SLNs, p \ 0.001). 12 We did not identify tumor histology, nuclear grade, multifocality, hormone status, or presence of lymphovascular invasion to be associated with the removal of additional lymph nodes in our study.
The influence of the ACOSOG Z0011 criteria on SLNB was recently reported by Robinson et al. 9 They hypothesized that surgeons would either place less importance on axillary lymph nodes, resulting in fewer SLNs being removed, or more importance and thus potentially remove more SLNs, because cALND was no longer being performed unless C2 nodes were positive. In either scenario, the ACOSOG Z0011 trial could be a potential source of bias, either for undersampling or oversampling the clinically negative axilla. In their single-institution study of 923 patients undergoing BCT for T1-2, clinically node-negative breast cancer, they found that the mean and median numbers of SLNs removed for the entire cohort were 2.7 and 2, respectively. The authors looked at the number of SLNs removed before and after both presentation and publication of the Z0011 trial. The mean number of SLNs removed before presentation of the trial was 2.7 [95 % confidence interval (CI) 2.6-2.8] compared with 2.6 (95 % CI 2.4-2.7) after presentation (p = 0.19). Similarly, the mean number of SLNs removed before trial publication was 2.7 (95 % CI 2.6-2.8) compared with 2.5 (95 % CI 2.4-2.7) after trial publication (p = 0.10). In addition, the authors found no difference in SLNs removed before or after Z0011 implementation when patients were divided into three age groups (B50, B60, and B70 years). In contrast to the study by Robinson et al., we found that as age decreased, the mean number of SLNs removed increased in the post-Z0011 cohort (p \ 0.0001).
In a prior study from our institution, the impact of ECE on the burden of axillary disease was evaluated in 11,730 patients meeting Z0011 criteria. 13 Patients with ECE were older (57 vs. 54 years of age, p = 0.001), had larger tumors (2.0 vs. 1.7 cm; p \ 0.0001), multifocal tumors (p = 0.006), hormone-positive tumors (p = 0.016), and lymphovascular invasion (p \ 0.0001). On multivariate analysis, C2 mm of ECE was the strongest predictor of C4 positive nodes on cALND [odds ratio (OR) 14.2], indicating that the presence and amount of ECE is an important indicator of nodal disease burden. In a study by Dengel et al., the presence of ECE, involvement of C3 SLNs, and matted nodes identified patients at high risk of nodal disease in ACOSOG Z0011-eligible patients and represented a subset of patients who were appropriately treated with cALND.
14 Similarly, Stitzenberg et al. found that ECE was highly predictive of non-SLN involvement on multivariate analysis [odds ratio (OR) 6.04, 95 % CI 1.5-24.2, p = 0.01]. 15 ECE was associated with the removal of more SLNs in our study (p = 0.001). While the presence of ECE is not known at the time of SLN, the presence of C2 mm of ECE predicts a possibility for greater tumor burden in the axilla and may serve as an indication for cALND, even if \3 SLNs are positive at the time of SLNB.
The National Comprehensive Cancer Network guidelines were updated in 2011 to include results of the Z0011 trial as standard of care. Several studies have assessed the impact of the trial on clinical practice. Wright et al. found that ALND (p \ 0.001) and intraoperative SLN analysis (p \ 0.001) declined after implementation of Z0011 criteria at their institution. 16 The authors found that patients with ECE (OR 12.8, 95 % CI 2.5-67.1) or those patients undergoing reoperative surgery (OR 10.8, 95 % CI 2.6-44.4) were more likely to undergo ALND. Robinson et al. found their rate of completion ALND after trial publication decreased from 83 % to 62 % (p \ 0.01). 9 Caudle et al. found that the rate of ALND decreased after implementation of Z0011 from 85 to 24 % (p \ 0.001). 17 The authors noted that surgeons were more likely to perform ALND in patients with larger tumors (2.2 vs. 1.5 cm, p = 0.09), lobular histology (p = 0.001), fewer SLNs harvested (1 vs. 3, p = 0.09), larger SLN metastasis size (4 vs. 2.5 mm, p = 0.19), ECE (20 vs. 6 %, p = 0.16), and in patients with a higher probability of positive non-sentinel lymph nodes (p = 0.03). At our institution, Dengel et al. prospectively assessed a cohort of patients undergoing BCT who met ACOSOG Z0011 criteria and found that 84 % of patients had ALND omitted since implementation of the trial.
14 In our current study, the rate of ALND decreased from 16.0 to 2.4 %, indicating that implementation of the Z0011 criteria has been adopted successfully into our clinical practice. To our knowledge, our study is the largest examining the impact of the Z0011 criteria on SLNB. The rate of ALND decreased in the post-Z0011 cohort, in keeping with our institutional acceptance of Z0011 criteria. We noted a slightly higher proportion of patients who had C4 SLNs harvested in the post-Z0011 cohort compared with the pre-Z0011 cohort. This may be a reflection of a bias for removal of all potential SLNs as no completion ALND is to be performed in patients who met Z0011 criteria.
CONCLUSIONS
Consistent with our prior study, we found young age and large tumor size to be associated with a greater number of SLNs removed at SLNB. Since adoption of the ACOSOG Z0011 trial criteria, we found the mean number of SLNs removed changed very little (2.8 before, 2.9 after), with significantly fewer patients undergoing ALND for B2 positive SLNs. We noted a slight shift in the removal of C4 SLNs in the post-Z0011 cohort, possibly representing an additional bias to remove all potential SLNs during the SLNB. Surgeons should be aware of factors that may potentially influence the removal of a greater number of sentinel nodes.
